Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 17;12:5751–5765. doi: 10.2147/OTT.S208924

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Oridonin overcomes PANC-1/Gem cell gemcitabine resistance by regulating LRP1/ERK/JNK signaling. (A) Expression of LRP1, ERK1/2, phosphorylated-ERK1/2, JNK1/2/3, phosphorylated-JNK, and NF-κB were examined in shNC and shLRP1 cells. The same proteins were detected in PANC-1/Gem cells treated with gemcitabine, oridonin or both for 24 h. (B) Xenografts from mice were immunochemically stained using LRP1 antibodies.

Abbreviations: LRP1, low-density lipoprotein receptor protein 1; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; NF, nuclear factor; shLRP1, short hairpin LRP1; shNC, non-silencing control shRNA (shNC).